Screener / SEC EDGAR /CIK 0001759425 /10-K filed Feb 25, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Mirum Pharmaceuticals, Inc. MIRM

Compare with peers Embed
What it said it expected, against what it reported

2 targets with a reported result

Releases of the last 3 years
Above the range 2 above the last range given
Within the range 0 of 2 range targets
Below the range 0 below the last range given

The numbers MIRM said it expected, in its earnings releases, next to what it then reported for the same period.

Target by target

Each target, with the sentence it came from · release and 10-Q or 10-K

The last range givenReported, abovewithin or keptbelow or missed
TargetWhat the company saidReportedResult
Revenue
Fiscal 2026
Given $630.00M to $650.00M release Jan 12, 2026
Kept $630.00M to $650.00M release Feb 25, 2026
Raised $660.00M to $680.00M release May 6, 2026
Raised $680.00M to $700.00M release Aug 5, 2026
Raised $715.00M to $720.00M release Nov 3, 2026
– Not reported yet
The company's words
– 2026 expected global net product sales of $630 million to $650 million release Jan 12, 2026
– 2026 expected global net product sales of $630 million to $650 million release Feb 25, 2026
– 2026 net product sales guidance increased to $660 to $680 million release May 6, 2026
– 2026 net product sales guidance increased to $680 million to $700 million release Aug 5, 2026
– Q3 2026 net product sales of $185.7 million; 2026 net product sales guidance increased to $715 million to $720 million release Nov 3, 2026
Revenue
Fiscal 2025 (ended Dec 31, 2025)
Given $420.00M to $435.00M release Jan 13, 2025
Kept $420.00M to $435.00M release Feb 26, 2025
Raised $435.00M to $450.00M release May 7, 2025
Raised $490.00M to $510.00M release Aug 6, 2025
Raised $500.00M to $510.00M release Nov 4, 2025
$521.31M
10-K filed 2026-02-25
Above the range
The company's words
– 2025 expected global net product sales of $420 million to $435 million release Jan 13, 2025
2025 expected global net product sales of $420 million to $435 million release Feb 26, 2025
Commercial: Raising full year revenue guidance to $435 to $450 million release May 7, 2025
– 2025 revenue guidance increased to $490 to $510 million release Aug 6, 2025
– 2025 revenue guidance updated to $500 to $510 million release Nov 4, 2025
Revenue
Fiscal 2024 (ended Dec 31, 2024)
Given $310.00M to $320.00M release Feb 28, 2024
Kept $310.00M to $320.00M release Aug 7, 2024
$336.89M
10-K filed 2025-02-26
Above the range
The company's words
2024 expected global net product sales of $310 million to $320 million release Feb 28, 2024
Second quarter global net product sales of $77.8 million, on track to achieve full-year guidance of $310 to $320 million release Aug 7, 2024

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (15 releases since 2024-01-08), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Sources

The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.

Also

Earnings releases: each release in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/MIRM/export.csv") into a cell.

Next:Archive
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.